LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.43
+43.27%Nov 4, 2026, 21:05 UTC
Lyell Immunopharma, Inc. reported financial results and business highlights for the third quarter ended September 30, 2026.
Source:Nov 4, 2026, 14:02 UTC
Lyell Immunopharma, Inc. entered into a securities purchase agreement for a private placement of approximately $80 million of its common stock.
Source:Sep 10, 2026, 20:05 UTC
Lyell Immunopharma completed the technology transfer of its GCC-targeted CAR T-cell candidate LYL273 to its LyFE Manufacturing Center in Bothell, Washington, following FDA review.
Source:Aug 6, 2026, 00:00 UTC
Lyell Immunopharma reported its Q2 2026 financial results, with revenue of $4,000, a GAAP net loss of $44.8 million, and cash and marketable securities of $228.0 million as of June 30, 2026.
Jul 6, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Lynn Seely, M.D. as a Class III director, effective June 30, 2026.
Jun 8, 2026, 14:21 UTC
Lyell Immunopharma provided a safety update on its LYL273 treatment in a Phase 1 clinical trial for relapsed or refractory metastatic colorectal cancer.
Source: